165 related articles for article (PubMed ID: 24752990)
1. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3.
Muvaffak A; Pan Q; Yan H; Fernandez R; Lim J; Dolinski B; Nguyen TT; Strack P; Wu S; Chung R; Zhang W; Hulton C; Ripley S; Hirsch H; Nagashima K; Wong KK; Jánne PA; Seidel-Dugan C; Zawel L; Kirschmeier PT; Middleton RE; Morris EJ; Wang Y
Mol Cancer Res; 2014 Jul; 12(7):1055-66. PubMed ID: 24752990
[TBL] [Abstract][Full Text] [Related]
2. Encephalomyocarditis virus 3C protease attenuates type I interferon production through disrupting the TANK-TBK1-IKKε-IRF3 complex.
Huang L; Xiong T; Yu H; Zhang Q; Zhang K; Li C; Hu L; Zhang Y; Zhang L; Liu Q; Wang S; He X; Bu Z; Cai X; Cui S; Li J; Weng C
Biochem J; 2017 Jun; 474(12):2051-2065. PubMed ID: 28487378
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of endogenous regulation of the type I interferon response by suppressor of IκB kinase epsilon (SIKE), a novel substrate of TANK-binding kinase 1 (TBK1).
Marion JD; Roberts CF; Call RJ; Forbes JL; Nelson KT; Bell JE; Bell JK
J Biol Chem; 2013 Jun; 288(25):18612-23. PubMed ID: 23649622
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
5. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
7. Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks.
Chakraborty S; Li L; Puliyappadamba VT; Guo G; Hatanpaa KJ; Mickey B; Souza RF; Vo P; Herz J; Chen MR; Boothman DA; Pandita TK; Wang DH; Sen GC; Habib AA
Nat Commun; 2014 Dec; 5():5811. PubMed ID: 25503978
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
9. DOK3 is required for IFN-β production by enabling TRAF3/TBK1 complex formation and IRF3 activation.
Kim SS; Lee KG; Chin CS; Ng SK; Pereira NA; Xu S; Lam KP
J Immunol; 2014 Jul; 193(2):840-8. PubMed ID: 24929003
[TBL] [Abstract][Full Text] [Related]
10. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1.
Lu LL; Puri M; Horvath CM; Sen GC
J Biol Chem; 2008 May; 283(21):14269-76. PubMed ID: 18362155
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
12. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
13. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway.
Tanaka Y; Chen ZJ
Sci Signal; 2012 Mar; 5(214):ra20. PubMed ID: 22394562
[TBL] [Abstract][Full Text] [Related]
14. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
Barbie DA; Tamayo P; Boehm JS; Kim SY; Moody SE; Dunn IF; Schinzel AC; Sandy P; Meylan E; Scholl C; Fröhling S; Chan EM; Sos ML; Michel K; Mermel C; Silver SJ; Weir BA; Reiling JH; Sheng Q; Gupta PB; Wadlow RC; Le H; Hoersch S; Wittner BS; Ramaswamy S; Livingston DM; Sabatini DM; Meyerson M; Thomas RK; Lander ES; Mesirov JP; Root DE; Gilliland DG; Jacks T; Hahn WC
Nature; 2009 Nov; 462(7269):108-12. PubMed ID: 19847166
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of NF-κB inducing kinase underlies constitutive NF-κB activation in lung cancer cells.
Saitoh Y; Martínez Bruyn VJ; Uota S; Hasegawa A; Yamamoto N; Imoto I; Inazawa J; Yamaoka S
Lung Cancer; 2010 Dec; 70(3):263-70. PubMed ID: 20338663
[TBL] [Abstract][Full Text] [Related]
16. UBQLN2 Promotes the Production of Type I Interferon via the TBK1-IRF3 Pathway.
Chen T; Zhang W; Huang B; Chen X; Huang C
Cells; 2020 May; 9(5):. PubMed ID: 32413959
[TBL] [Abstract][Full Text] [Related]
17. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells.
Kim JY; Welsh EA; Oguz U; Fang B; Bai Y; Kinose F; Bronk C; Remsing Rix LL; Beg AA; Rix U; Eschrich SA; Koomen JM; Haura EB
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12414-9. PubMed ID: 23836654
[TBL] [Abstract][Full Text] [Related]
18. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells.
Carlisle DL; Liu X; Hopkins TM; Swick MC; Dhir R; Siegfried JM
Pulm Pharmacol Ther; 2007; 20(6):629-41. PubMed ID: 17015027
[TBL] [Abstract][Full Text] [Related]
19. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
20. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
